Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00999401 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Cyclacel Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
NCT00999401 is a Phase 1 study that has completed, run by Cyclacel Pharmaceuticals. The registered enrollment target is 103 participants.
The verdict
NCT00999401, a Phase 1 study, has completed, sponsored by Cyclacel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
Study Summary
A study of sequential administration of oral sapacitabine and oral Seliciclib in patients with advanced solid tumors.
Interventions
- DRUG sapacitabine and seliciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2009-04 |
| Est. Completion | 2019-08-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00999401
The ClinicalTrials.gov registry entry for NCT00999401 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyclacel Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sapacitabine and seliciclib is the first listed.
NCT00999401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00999401 about?
NCT00999401 is a clinical study titled "A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors". A study of sequential administration of oral sapacitabine and oral Seliciclib in patients with advanced solid tumors.
What is the current status of trial NCT00999401?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2009-04. Estimated completion is 2019-08-13.
What interventions are being tested in trial NCT00999401?
The interventions under investigation include: sapacitabine and seliciclib (DRUG).
Who is sponsoring clinical trial NCT00999401?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.